On the Bookshelf: 'Cancer Is a Parasite' Challenges Medical Orthodoxy and Offers Hope to Millions of Cancer Patients

Key Takeaways

• Fenbendazole, a veterinary dewormer, is presented as a cancer therapy
• Author cites over 20 case reports of remission using fenbendazole
• Global deworming programs correlate with roughly half U.S. cancer rates
• Drug costs pennies per dose, far cheaper than standard oncology drugs
• Supple claims efficacy was hidden since 1970s 'oncodazole' discovery

Pulse Analysis

The launch of *Cancer Is a Parasite* has ignited a debate that bridges oncology, parasitology, and drug repurposing. Supple, leveraging his neuroscience background, assembles a compelling dossier of laboratory data showing fenbendazole’s ability to disrupt microtubules, impair glucose metabolism, and trigger tumor‑suppressor pathways. By weaving together research from Johns Hopkins and MD Anderson, he demonstrates that the drug’s anti‑cancer properties have been documented for decades yet remain outside mainstream treatment protocols.

Beyond laboratory evidence, the book presents a mosaic of real‑world outcomes. More than twenty patient narratives detail complete remissions in aggressive brain, breast, and melanoma cancers after conventional therapies failed. Supple also points to an epidemiological pattern: nations that routinely administer mass deworming agents report cancer incidence roughly half that of the United States. He suggests that a 1976 discovery named “oncodazole,” essentially fenbendazole for oncology, was deliberately obscured, potentially costing millions of lives.

If fenbendazole’s efficacy withstands rigorous clinical testing, the ramifications for the healthcare system are profound. At a cost of a few pennies per dose, the drug could undercut the multi‑million‑dollar price tags of chemotherapy and immunotherapy, making effective cancer care accessible in low‑resource settings. However, regulatory approval, large‑scale trials, and physician acceptance remain hurdles. The book’s call for immediate, serious investigation may accelerate research funding and spark a new wave of repurposing studies, offering hope to patients who have exhausted standard options.